Xeris Pharmaceuticals Inc (NASDAQ:XERS) has been working on developing ready-to-use (RTU) solutions for various therapeutic areas. The company has had breakthroughs in areas such as that of severe hypoglycemia and seizures. The two conditions require swift attention, yet the market does not have optional treatments that are not as burdensome as the present ones.
However, in its Q2 report of its financial results, Xeris has outlined its continued dedication to the communities suffering from such related conditions. It has accomplished significant milestones, including positive topline results from a Phase 2 clinical study evaluating pramlintide and insulin ready-to-use. These are potential treatment formulations for Type 1 diabetes.
Building the momentum of the recent launch of Gvoke HypoPen
Despite numerous pandemic-related constraints, Xeris has been rising steadily. It has illustrated its helpfulness for individuals with diabetes and their families. The primary focus is now on the launch of the Gvoke HypoPen. Its positive results from the recent clinical developments have continued to strengthen the company’s balance sheet.
According to Xeris’ CEO Paul R. Edick, they are now building on the launch’s momentum. It has enhanced prescription growth to 72% quarter over quarter. More than 80% of patients can already access Gvoke (PFS and HypoPen) freely across all payers. The anticipation is that it will eliminate the financial load for commercially insured patients during the COVID-19 pandemic.
Breakthroughs in Pipeline Programs
“Our strong performance this quarter reflects Xeris’ dedication to the communities we serve… We’re very proud of what we’ve accomplished so far this year, despite the circumstances…’’ Edick highlighted.
The company has also been working on other candidates, which have performed exceedingly well in their trials. Its investigational ready-to-use diazepam formulation reported preliminary topline data from its Phase 1b study. Its glucagon formulation had positive results from the out-patient portion of its Phase 2 study.
The formulation is a treatment for exercise-induced hypoglycemia (EIH), and the results established a safety profile in a real-world setting. It is currently under review by the European Medicines Agency (EMA), and if authorized, the company says it will launch in 2021 in some European countries.